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Exendin‐4 enhances osteogenic differentiation of adipose
tissue mesenchymal stem cells through the receptor
activator of nuclear factor‐kappa B and osteoprotegerin
signaling pathway
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Abstract
The capability of mesenchymal stem cells (MSCs) to repair bone damage and
defects has long been investigated. The receptor activator of nuclear factor‐
kappa B (RANK), its ligand (RANKL) and the decoy receptor osteoprotegerin
(OPG) axis is crucial to keep the equilibrium between osteoblastic and
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osteoclastic activity. Exendin‐4 utilization increased bone formation and
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(Ad‐MSCs) osteogenic differentiation. Ad‐MSCs were isolated from rat
epididymal fat, followed by characterization and then differentiation into
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enhanced bone integrity. This study aimed to investigate the mentioned axis
and determine the effect of exendin‐4 upon adipose mesenchymal stem cells

osteocytes both in the presence or absence of exendin‐4. Osteogenic
differentiation was evaluated by alizarin red staining and the expression of
osteogenic markers; using reverse transcriptase‐quantitative polymerase chain
reaction, western blotting and enzyme‐linked immunoassay. MSCs derived
from rat epididymal fat were isolated and characterized, along with their
differentiation into osteocytes. The differentiated cells were alizarin red‐
stained, showing increased staining intensity upon addition of exendin‐4.
Moreover, the addition of exendin‐4 elevated the messenger RNA expression
levels of osteogenic markers; runt‐related transcription factor‐2 (RUNX‐2),
osteocalcin, and forkhead box protein O‐1 while reducing the expression of the
adipogenic marker peroxisome‐proliferator‐activated receptor‐gamma.
Exendin‐4 addition elevated OPG levels in the supernatant of osteogenic
differentiated cells. Moreover, exendin‐4 elevated the protein levels of
glucagon‐like peptide‐1 receptor and RUNX‐2, while decreasing both RANK
and RANKL. In conclusion, osteogenic differentiation of Ad‐MSCs is
associated with increased osteoblastic rather than osteoclastic activity.
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The findings of this study suggest that exendin‐4 can enhance Ad‐MSCs
osteogenic differentiation partially through the RANK/RANKL/OPG axis.
KEYWORDS

adipose mesenchymal stem cells, exendin‐4, osteocytes, osteoprotegerin
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INTRODUCTION

Stem cells are undifferentiated cells lacking tissue‐
specific markers. They are capable of self‐renewal,
proliferation, have long‐term viability and multilineage
potential.1 Mesenchymal stem cells (MSCs) are one
source of these stem cells. The description of multipotent
MSCs was first suggested in the 1970s by Friedenstein
and his colleagues manifesting the ability of bone marrow
cells to differentiate into osteoblasts.2,3 MSCs are potential source for regenerative cell therapy as they fulfill
most of the criteria required for cells to be used in cell
therapy. These cells can be available with abundant
quantities, and they can be harvested by a minimally
invasive procedure. In addition, they can differentiate
along multiple cell lineage in a reproducible manner.
More importantly, they can be transplanted to either an
autologous or allogeneic host safely and effectively. MSCs
isolated from adipose tissue fulfill most of these criteria
and attracted more attention as a rich abundant source of
MSCs from lipoaspirate.4
According to the International Society for Cell and
Gene Therapy (ISCT), cells to be classified as MSCs
should possess the following characteristics: first, they
must be adherent to plastic when grown under standard
culture conditions. Second, they should express mesenchymal markers such as cluster of differentiation (CD)
105, CD90, and CD73; while lacking hematopoietic
markers such as CD34 in most of the cells grown in
the culture medium. Finally, the cells should be capable
of differentiation into adipocytes, osteocytes and chondrocytes when subjected to standard in vitro differentiation conditions.5
MSCs were extensively tested for their capability to
improve defected bone tissues. For instance, MSCs were
used to regenerate cartilage where they are injected into
the injured tissue and then differentiate into chondrocytes producing cartilaginous matrix.6 Moreover, repairing bone defects by MSCs is also one of the approaches
that have been used in regenerative medicine.7
Exendin‐4, a natural analogue of glucagon‐like
peptide‐1 (GLP‐1), is secreted in the saliva of the Gila
monster in the southwestern United States.8 Exendin‐4
has been extensively studied in the field of stem cells
differentiation especially in differentiation into insulin

producing cells.9–11 Lately, it was found to be important
for osteogenic differentiation of MSCs as well.12 Interestingly, exendin‐4 was also found to promote the
proliferation and the survival of many types of cells.13,14
In addition, Zhou and coworkers, 2015, observed
beneficial effects of exendin‐4 on proliferation, migration
and survival of MSCs; apart from its inductive effects in
differentiation of MSCs into different lineages. These
effects add on the beneficiary effects of exendin‐4 in
clinical applications of MSCs.8 Actually, this data ignited
our interest in exploring exendin‐4 osteogenic effects
through this study.
Furthermore, studies have shown that exendin‐4
binds GLP‐1R, which is expressed in osteoblast cells to
improve bone mass, bone microstructure and bone
quality.15 Interestingly, it was established that GLP‐1R
expression increased with the increasing concentrations
and treatment time of exendin‐4, indicating that the
upregulation of GLP‐1R expression takes place upon
exendin‐4 utilization.16
During the process of bone remodeling, there is an
equilibrium between bone formation and bone resorption, which is regulated by a system composed of three
key proteins; RANK, its ligand RANKL and osteoprotegerin (OPG).17 OPG is well known as osteoclasts
inhibitor factor, which is a soluble receptor homologous
to tumour necrosis factor receptor. OPG is a soluble
decoy receptor which competes with RANK receptor to
bind to RANKL. In other words, OPG is an endogenous
antagonistic receptor which inhibits osteoclastogenesis
upon binding with RANKL, thus jamming the process of
bone resorption.18 Actually, the OPG–RANKL complex
counterbalances the effect of the RANK–RANKL complex, thus playing a crucial role in bone homeostasis.19
However, only few information is revealed about this axis
in osteogenic differentiation of MSCs.
Based on the previous knowledge, this study aimed
to inspect the RANK/RANKL/OPG axis during the
differentiation of rat adipose mesenchymal stem cells
(Ad‐MSCs) down the osteogenic differentiation as
well as to examine the impact of exendin‐4 on the
differentiation of Ad‐MSCs along the osteogenic
lineage and to trace the result of exendin‐4 utilization
on the enhancement of osteoblastic activity through
the inspected axis.
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MATERIALS A ND METHODS

2.1 | Isolation and culture of rat
adipose MSCs
The experiments and all the procedures were performed
according to the accepted guidelines; they were approved by
the ethical committee of the Faculty of Pharmacy, Cairo
University, Cairo, Egypt (approval number BC2460). The
animals (Sprague‐Dawley rats) were maintained under
controlled light and environmental conditions (12 h light/
12 h dark cycle at a constant temperature of 25 ± 2°C) with
free access to food and water. The animals were used for
isolation procedures 1 week after acclimatization.
Two 250–300 g male Sprague‐Dawley rats were used per
isolation. The rats were anaesthetized by intraperitoneal
injection of ketamine hydrochloride (33 mg/kg body weight)
and xylazine hydrochloride (13 mg/kg body weight) freshly
prepared cocktail as described previously.20 The rats were
euthanized by cervical dislocation. All animal carcasses were
kept at −20°C till safe disposal by incineration. Ad‐MSCs
were isolated from the epididymal fat as described
previously.21 Briefly, the fat tissue surrounding the epididymis was isolated and cut into small pieces. The tissue was
washed 4 times with phosphate buffered saline (PBS) to
remove any contaminating blood. Then the tissue was
digested with 0.1% collagenase type I at 37°C for 45 min till a
homogenous solution was formed. After centrifugation, the
supernatant was removed and the stromal vascular fraction
was washed with 1% bovine serum albumin (BSA), then re‐
centrifuged and the pellet was suspended in Dulbecco's
Modified Eagle Medium/Nutrient Mixture F‐12 (DMEM/
F12) media (Lonza) containing 10% fetal bovine serum (FBS)
(Gibco, Thermo Fisher) and penicillin/streptomycin/amphotericin (Gibco, Antibacterial‐Antimycotic) containing
100 U/ml Penicillin, 100 µg/ml Streptomycin and 0.25 µg/
ml of Amphotericin B (Gibco, Thermo Fisher) and 2 mM
L‐glutamine (Gibco, Thermo Fisher). On the following day,
the suspended cells were removed, and the media was
changed every other day. The cells were cultured till
cells reach 80%–90% confluence, this was designated
passage (P0). Then the cells were split using Trypsin‐
ethylenediaminetetraacetic acid into single‐cell suspension
and re‐cultured in larger volume, to allow further expansion.
This was designated passage 1 (P1). The cells were allowed
to expand till passage 3 (P3).22

2.2 | Characterization of the Ad‐MSCs
by immunophenotyping
Ad‐MSCs characterization was fulfilled through immunophenotyping by fluorescent activated cell sorting

ET AL.

(FACS) analysis for the mesenchymal marker CD90
and the hematopoietic markers CD34. CD90 is a
membrane glycoprotein which is highly expressed in
MSCs irrespective of the source.23 In addition, it was
found to hinder the MSCs differentiation; maintaining
them in the stemness state.24 Accordingly, CD90 is a
reliable mesenchymal CD marker in MSCs characterization. On the other hand, CD34 was found to be highly
expressed in hematopoietic stem cells,25 so MSCs should
lack its expression. Briefly, at passage 3, Ad‐MSCs were
treated with trypsin and then washed with PBS twice. A
total of 100 000 cells were incubated in the dark for
20 min at 4°C with either mouse anti‐rat CD90 monoclonal antibody labeled with fluoroisothiocyanate (FITC) or
anti‐CD34 phycoerythrin (PE) labeled (Stem cells Technologies, USA). Unstained cells acted as controls, then
the cells were washed and suspended in 500 μl of FACS
buffer to be analyzed by a CYTOMICS FC 500 Flow
Cytometer (Beckman Coulter) using CXP Software
version 2.2.

2.3 | Differentiation of Ad‐MSCs into
adipocytes, osteocytes, and chondrocytes
The differentiation of the isolated cells was done using
the human MSC functional identification kit (R&D
systems Inc.) which contained specially formulated
supplements to induce the differentiation of MSCs into
adipocytes, osteocytes and chondrocytes according to the
manufacturer's instructions. Briefly, cells were either
incubated with the adipogenic supplement or osteogenic
supplement in DMEM media (Gibco, Thermo Fisher)
with 10% FBS and antibiotic‐antimycotic solution (Gibco,
Thermo Fisher). On the other hand, for chondrogenic
differentiation, cells were incubated with serum‐free
DMEM/F12 (Lonza) containing ITS supplement supplied
with the kit composed of insulin, transferrin, selenious
acid, BSA, and linoleic acid; and chondrogenic supplement provided with the kit. The differentiation continued
for 21 days with changing the differentiation media every
3 days.
After 21 days, assessment of adipogenic differentiation was investigated by appearance of lipid vacuoles
under microscopic examination and oil red staining
(Sigma‐Aldrich). The osteogenic differentiation
was observed under the microscope using alizarin
red staining (Sigma‐Aldrich) of the calcium rich
extra cellular matrix. While the chondrogenic
differentiation was assessed using alcian 8GX blue
staining (Sigma‐Aldrich) for sulfated proteoglycan.
All images were taken using Olympus microscope,
Japan.
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2.4 | Osteogenic differentiation of
Ad‐MSCs in the absence or presence of
exendin‐4
Ad‐MSCs were induced for osteogenic differentiation
with osteogenic differentiation media containing 50 nM
dexamethasone
(Sigma
Aldrich
Merck),
10 mM
β‐glycerophosphate (Sigma Aldrich Merck) and 50 μg/ml
ascorbic acid (Sigma Aldrich Merck) in DMEM/F12 with
10% FBS, Antibacterial‐Antimycotic as in proliferation media
as described previously.26 To examine the effect of exendin‐4,
osteogenic differentiation was done in the presence of 20 nM
exendin‐4 (Sigma Aldrich) throughout the whole 21‐day
induction period. This exendin‐4 concentration was decided
based on previous studies showing that; by using several
concentrations of exendin‐4 from 10 to 20 nM, the 20 nM
concentration was safe and effective on both bone marrow
and adipose MSCs.8,27 Cells were maintained in complete
proliferation media serving as control cells. Osteogenic
differentiation either with or without exendin‐4 was carried
out for 21 days and media was changed every 3 days.
Afterwards, osteogenic differentiation and exendin‐4 effects
were assessed using alizarin red staining, and also by
examining various osteogenic markers expression; using
quantitative PCR and western blot at 1‐week intervals during
the differentiation process.
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2.6 | RNA extraction, complementary
DNA (cDNA) synthesis, and reverse
transcriptase‐quantitative polymerase
chain reaction (RT‐qPCR)
Both groups of osteogenic differentiated Ad‐MSC either
in the absence or presence of exendin‐4; together with
control cells were collected and washed with PBS.
Afterwards, total RNA was isolated using TRIzol Reagent
(Life Technologies) according to the manufacturer's
instructions. Briefly, 3 × 106 cells were treated by 1 ml
TRIzol, followed by extraction using chloroform and
isopropanol. The cDNA was prepared by VersoTM cDNA
synthesis kit (Thermo Scientific) using 0.5 µg RNA
according to the manufacturer's instructions. Each RT‐
qPCR reaction was done using 4 ng cDNA using SYBR
Green Master Mix (Applied Biosystems). β‐actin was
used as internal control. Relative expression levels were
calculated by ΔΔCt method. The messenger RNA
(mRNA) expression of various osteogenic markers runt‐
related transcription factor‐2 (RUNX‐2), osteocalcin (OC),
collagen‐1 (Col‐1), forkhead box protein O‐1 (FOXO‐1) as
well as the adipogenic marker peroxisome‐proliferator‐
activated receptor‐gamma (PPAR‐γ) was carried out by
RT‐qPCR. In Table 1 target genes' forward and reverse
primers are stated. All RT‐qPCR analyses were performed on StepOnePlus Real‐Time PCR System (Applied
Biosystems).

| Alizarin red staining

Alizarin Red Solution (ARS) has long been used as an
available and easy‐to‐use stain for the staining of calcium
phosphate‐rich monolayers resulting from osteogenic
differentiation of MSCs. This study followed the same
procedure as described previously.26 Briefly, after initial
equal number of Ad‐MSCs has been induced for
osteogenic differentiation for 21 days, cells were washed
with PBS and fixed with 10% neutral formalin for 15 min
at room temperature. Then, 1 ml of 40 mM ARS was
added, and cells were incubated for 20 min at room
temperature with gentle shaking. Afterwards, any
remaining dye was washed away using double distilled
water, and then stained cells were visualized using
Olympus inverted microscope (Olympus).
After imaging the cells, ARS was extracted for
quantification of the stain. This was done by adding
10% acetic acid to the stained cells for 30 min. Then the
loosely attached cells were collected with the dye,
centrifuged and the supernatant was quantified using
spectrophotomer at 405 nm (Jenway). All the procedures
were done on control cells under proliferation media,
osteogenic induced cells with or without exendin‐4.
Results were expressed as absorbance at 405 nm.

2.7 | OPG determination using enzyme‐
linked immunosorbent assay (ELISA)
The secreted OPG was determined in the conditional
media of the osteogenic‐induced cells with or without
exendin‐4, using Quantikine® ELISA Mouse OPG/
TNFRSF11B Immunoassay (R&D) as per the manufacturer's instructions. The kit was used for the
quantitative determination of rat OPG concentrations
in cultured cells' supernatant.28 Supernatants from
control cells, osteogenic differentiated cells (Osteo)
and osteogenic differentiated cells with exendin‐4
(Osteo+Ex) were assayed in triplicates. All measures
were done in ClarioStar® microplate reader (BMG
Labtech).

2.8 | Sodium dodecyl
sulfate–polyacrylamide gel electrophoresis
(SDS‐PAGE) and western blot
After differentiation, cells were collected for whole cell
protein extracts and western blot. Whole cell extracts
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Sequence of primers used for the RT‐qPCR

Genes

Forward primer 5′−3′

Reverse primer 5′−3′

RUNX‐2

CAACTTCCTGTGCTCCGTG

CGGTAACCACGGTCCCAT

OC

GCATCAAAACAGAGACCAGGA

TCTCGTCTGGGCTGATCTTC

Col‐1

TGTTCAGCTTTGTGGACCTC

GCCATTGTGGCAGATACAGA

FOXO‐1

GAACGACCTCATGGACGGAGA

GGGGTGAAGGGCATCTTTGGA

PPAR‐γ

ACCTCTTTGCTCTGCTCCTG

TAAAGTCCTTCCCGCTGACC

β‐actin

TACGAGAAGCTCCTGTGGAC

GCTGCATCGGACAAGTTTCT

Abbreviations: Col‐1, collagen‐1; FOXO‐1, forkhead box protein O‐1; OC, osteocalcin; PPAR‐γ, peroxisome‐proliferator‐activated receptor‐gamma; RT‐qPCR,
reverse transcriptase‐quantitative polymerase chain reaction; RUNX‐2, runt‐related transcription factor‐2.

were prepared from control, Osteo and Osteo+Ex cells
using RIPA buffer, supplemented with protease/
phosphatase inhibitor tablets (Thermo Fisher).
Briefly, cells were homogenized in the RIPA buffer
for half an hour at 4°C, followed by high‐speed
centrifugation to remove cell debris. The supernatant,
the whole cell extract, was quantified using Pierce™
BCA protein quantification kit (Thermo Fisher). A
total of 30 μg of protein were loaded on 4%–20%
precast Invitrogen Novex® Tris‐Glycine polyacrylamide gels (Thermo Fisher) after denaturation
in Laemmli sample buffer. Then, the proteins were
electrically transferred to nitrocellulose membrane
(Thermo Fisher). The membrane was then probed
over night at 4°C with the following antibodies:
mouse anti‐rat β‐actin (1:1000 Cell Signaling
Technologies), mouse anti‐rat GLP‐1R (Santa‐Cruz),
rabbit anti‐rat RUNX‐2 (1:500 Novus Biologicals),
rabbit anti‐rat RANK and rabbit anti‐rat RANKL
(Cell Signaling Technologies). Then, excess primary
antibody was washed, and the membrane was
incubated with the corresponding anti‐mouse or
anti‐rabbit secondary antibodies (Cell Signaling
Technologies). After washing, the bands were
visualized using SuperSignal™ West Femto Maximum
Sensitivity Substrate (Thermo Fisher). The membrane
was visualized using C‐digit Blot Scanner
(LI‐COR).

2.9

| Statistical analysis

All data are presented as mean ± standard error of mean.
The comparisons between means were done by either t
test (for two samples) or one‐way analysis of variance test
for more than two samples using Bonferroni post hoc
test. Means were considered significantly different at p
values <.05. All statistical analyses were carried out
using Graph Pad Prism‐version 6.

3 | R ES U L T S
3.1 | Adipose tissue is a good source of
MSCs accomplishing all MSCs properties
As shown in Figure 1A, cells with fibroblast‐like
morphology started to appear at day 7 postisolation.
The cells resembled MSCs morphology. They were
homogenous and showed great culture properties.
Moreover, they exhibited all MSCs properties proposed
by the ISCT. First, they were adherent to plastic. Second,
flow cytometric analyses for MSCs and hematopoietic
specific CD markers were performed. Immunophenotyping of the isolated cells as shown in Figure 1B revealed
that almost all the cells were negative for hematopoietic
marker CD34, while being positive for MSCs marker
CD90, this was manifested in the expression levels of
these markers, CD34+ cells: 10% while CD90+ cells: 79%.
Upon differentiation of the cells along the mesenchymal lineages, the cells were confirmed to exhibit adipogenic
differentiation ability; examined using oil red stain for lipid
vacuoles in contrast to control undifferentiated cells.
Moreover, they were capable of osteogenic differentiation,
which was determined by alizarin red staining of calcium
rich extracellular matrix in comparison with the control
undifferentiated cells. Finally, the isolated cells were capable
of chondrogenic differentiation, and that was assessed using
alcian 8GX blue stain for sulfated proteoglycan in comparison with the control undifferentiated cells Figure 1C. These
results indicate that the isolated cells were relatively
homogenous populations, showing all characteristics of
mesenchymal phenotype of the Ad‐MSCs.

3.2 | Exendin‐4 enhances the osteogenic
differentiation of Ad‐MSCs
To assess the effect of exendin‐4 on osteogenic differentiation of Ad‐MSCs, the osteogenic differentiation was
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F I G U R E 1 Characterization of the isolated MSCs from adipose tissue (A) Microphotographs showing Ad‐MSCs exhibiting fibroblast‐
like morphology characteristic of MSCs at passage 0 (P0) and after 3 passages (P3). (B) Flowcytometric analysis of Ad‐MSCs showing control
unstained cells, CD90‐FITC showing 79% of cells are CD90 positive and CD34 PE showing that almost all cells are negative; only 10% are
CD34 positive. (C) Cells differentiated into adipocytes, osteocytes and chondrocytes showing oil red staining, alizarin red staining, and
alcian blue staining, respectively (right panel) as compared to control undifferentiated cells (left panel). Ad‐MSC, adipose mesenchymal
stem cell; CD, cluster of differentiation

performed either in the absence or presence of 20 nM
exendin‐4. After 3 weeks of differentiation (W3), cells
were stained using alizarin red. As shown in Figure 2A,
the osteogenic differentiated cells (Osteo) showed red
staining with alizarin as compared to control cells.
Interestingly, cells differentiated in the presence of
exendin‐4 (Osteo+Ex), showed more staining intensity
with alizarin. Colorimetric quantification of the alizarin
dye confirmed this finding as shown in Figure 2B, where
OsteoW3 cells showed almost fourfolds more alizarin
staining as compared to control cells. Moreover, Osteo
+Ex W3 cells showed almost twofolds more staining as
compared to non‐exendin‐4 differentiated cells (control:
Abs = 0.32 ± 0.15; Osteo W3: Abs = 1.32 ± 0.16 and Osteo
+Ex W3: Abs = 2.35 ± 0.23; p < .05).
Then, expression of some osteogenic genes was
examined upon differentiation. As shown in Figure 3A,
osteogenic differentiation caused significantly increased
expression levels of RUNX‐2; a master regulator of
osteogenic differentiation; with 30% elevation of the
control cells starting from week‐1 of differentiation (W1),
and it kept this elevation through week‐2 (W2) reaching
almost twofolds of the control at the end of differentiation in week‐3 (W3) (W1: 1.3 ± 0.095, W2: 1.9 ± 0.15, and

W3: 1.9 ± 0.14; p < .05). Interestingly, differentiation
accompanied with exendin‐4 showed significantly elevated expression pattern of RUNX‐2, reaching almost
twofolds starting from W1 (W1 + Ex), with modest
increase to 2.5‐folds of the control cells in W2, and it
maintained this elevated level in W3 without further
increase (W1 + Ex: 2.1 ± 0.062; W2 + Ex: 2.4 ± 0.28, and
W3 + Ex: 1.8 ± 0.07; p < .05).
As for OC, another osteogenic marker, showed significant elevation reaching twofolds of the control levels at W1.
OC keeps this elevation through W2 but declined in W3
(W1: 2.2 ± 0.11; W2: 1.8 ± 0.06, and W3: 1.16 ± 0.12; p < .05).
Interestingly, exendin‐4 caused a significant elevation of this
marker reaching almost threefolds the control, and kept this
elevation till reaching the end of differentiation (W1 + Ex:
3.25 ± 0.18; W2 + Ex: 1.7 ± 0.05, and W3 + Ex: 2.7 ± 0.23;
p < .05) (Figure 3B).
As for the other marker, named Col‐1, which is an
early marker of osteogenic differentiation.29 Figure 3C
shows that Col‐1 expression initially increased reaching
almost threefolds than that of control. However, it started
to decline significantly reaching almost the same control
level in W2, with further decline to half the expression of
the control cells in W3 (W1: 2.95 ± 0.23, W2: 1.09 ± 0.16,
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F I G U R E 2 Exendin‐4 enhances osteogenic differentiation of Ad‐MSCs and alizarin red staining (A) Microphotographs showing
osteogenic differentiated Ad‐MSCs without exendin‐4 (Osteo W3) and with exendin‐4 (Osteo+Ex W3) exhibiting more alizarin red staining
as compared to undifferentiated cells (control), Osteo+Ex W3 cells showed more staining as compared to Osteo W3 cells. (B) Colorimetric
quantification of alizarin red staining showed more absorbance of alizarin‐red in Osteo+Ex cells as compared to either osteo cells or control
cells. a: mean is significantly different from control at p < .05. b: mean is significantly different from osteoW3 p < .05 Control: undifferentiated
cells, OsteoW3: osteogenic differentiated cells, Osteo+Ex W3: osteogenic differentiated cells in presence of exendin‐4, W3: 3 weeks.
Ad‐MSC, adipose mesenchymal stem cell

and W3: 0.50 ± 0.04; p < .05). As for exendin‐4, it caused
significant less elevation of Col‐1 in W1 reaching only
twofolds the control levels. The levels showed further
decline reaching half that of the control level at the end
of differentiation (W1 + Ex: 1.8 ± 0.24, W2 + Ex:
0.63 ± 0.14, and W3 + Ex:0.51 ± 0.017; p < .05).
Then the expression of another transcription factor was
tested associated with the osteogenic differentiation of Ad‐
MSCs, which is FOXO‐1. It was significantly elevated during
osteogenic differentiation reaching almost sevenfolds in W1,
approaching ninefolds at the end of differentiation (W1:
7.09 ± 0.29, W2: 5.30 ± 0.21, and W3: 8.69 ± 0.25; p < .05).
Interestingly, exendin‐4 maintained this elevation in W1 and
W2, with slight decrease towards the end of differentiation
(W1 + Ex: 7.34 ± 0.12, W2 + Ex:6.69 ± 0.43, and W3 + Ex:
5.34 ± 0.46; p < .05) (Figure 3D).
As for PPAR‐γ, which represents a balance, together
with FOXO‐1 between osteogenic and adipogenic differentiation.30 Interestingly, osteogenic differentiation
showed significant elevation of PPAR‐γ, starting from
sevenfolds expression at W1 and ended up with almost
sixfolds towards the end of differentiation (W1:

7.023 ± 0.28, W2: 6.73 ± 0.49, and W3: 5.75 ± 0.61;
p < .05). On the other hand, although the presence of
exendin‐4 caused significant initial elevation of PPAR‐γ
reaching almost 10 folds the control levels. However,
exendin‐4 decreased this elevation towards the end of
differentiation, reaching only less than fivefolds of the
control levels (W1 + Ex: 10.20 ± 0.94, W2 + Ex:
7.44 ± 0.74, and W3 + Ex: 4.9 ± 0.26; p < .05) (Figure 3E).

3.3 | Exendin‐4 enhances OPG secretion
and affects the RANK/RANKL/OPG axis
This study evaluated the effect of exendin‐4 on the
RANK/RANKL/OPG axis. The secreted OPG concentration was first determined in the supernatant of control,
osteogenic differentiated cells (Osteo) and osteogenic
differentiated cells with exendin‐4 (Osteo+Ex). Figure 4A
showed that OPG was very slightly elevated in control
cells starting from day 3 (D3) after differentiation
reaching significant elevation only in D21 (D3:
81 ± 9.8 pg/ml and D21: 197 ± 16 pg/ml; p < .05).
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F I G U R E 3 Exendin‐4 enhances the expression of osteogenic markers in Ad‐MSCs: Osteogenic differentiated cells and osteogenic
differentiated cells with exendin‐4 showed (A) increased expression of RUNX‐2, (B) increased expression of OC, (C) decreased expression of
Col‐1, (D) increased expression of FOXO‐1 and (E) decreased expression of PPAR‐γ. a: mean is significantly different from control at p < .05.
b: mean is significantly different from osteoW1 p < .05. c: mean is significantly different from osteoW2 p < .05. d: mean is significantly different
from osteoW3 p < .05. e: mean is significantly different from osteo + ExW1 p < .05. Control: undifferentiated cells, Osteo: osteogenic
differentiated cells, Osteo+Ex: osteogenic differentiated cells in presence of exendin‐4, W1: week‐1, W2: week‐2, W3: 3 weeks. Ad‐MSC,
adipose mesenchymal stem cell; FOXO‐1, forkhead box protein O‐1; OC, osteocalcin; PPAR‐γ, peroxisome‐proliferator‐activated receptor‐
gamma

However, both Osteo cells and Osteo+Ex cells showed
significant elevation in concentration of OPG starting from
D5 and maintained this significant elevation till D21 (Osteo
D3: 85 ± 10 pg/ml, Osteo D21: 308 ± 4.5 pg/ml; Osteo+Ex
D3: 115 ± 23, and Osteo+Ex D21: 269 ± 14 pg/ml; p < .05).
Although both Osteo and Osteo+Ex cells had comparable
levels of OPG at D3, but Osteo+Ex showed significant
elevated levels of OPG only in D14, but failed to maintain
this elevation till D21 (Osteo D14: 308 ± 2.6 and Osteo+Ex
D14: 396 ± 14 pg/ml; p < .05).
To attain deeper knowledge of exendin‐4 effect on
osteogenic differentiation and its impact on RANK/
RANKL/OPG axis, the proteins were examined by
immunoblotting. As shown in Figure 4B, first, the
expression of GLP‐1R was examined in those Ad‐MSCs,
which showed significant expression in control cells. GLP‐
1R expression decreased upon osteogenic differentiation

initially in W1 and W2 but returned to control levels
towards W3. Interestingly, exendin‐4 increased expression
of GLP‐1R upon osteogenic differentiation especially in
W2. As for RUNX‐2, its expression increased in the first 2
weeks of osteogenic differentiation but declined in the
third week. Meanwhile, osteogenic differentiation in the
presence of exendin‐4 showed modest elevation of RUNX‐
2 expression as compared to osteogenic cells without
exendin‐4 in the first 2 weeks, with a similar decline in the
third week.
As for the RANK and RANKL expression, Figure 4B
showed that osteogenic differentiation increased the expression of RANK within the first 2 weeks with a decline in the
third week. Exendin‐4 also increased the RANK expression,
reaching its peak at week 2 of differentiation. On the other
hand, although control Ad‐MSCs showed some expression of
RANKL, osteogenic differentiation was associated with a

914

|

HABIB

ET AL.

F I G U R E 4 Exendin‐4 modulated RANK/RANKL/OPG axis: (A) OPG secreted levels in the supernatant of undifferentiated Ad‐MSCs
(control), osteogenic differentiated cells (Osteo), and osteogenic differentiated cells with exendin‐4 (Osteo + Ex). Points are taken on day 3
(D3), D5, D7, D14, and D21 of differentiation. *: mean is significantly different from control D3 at p < .05. a: mean is significantly different
from control D5 at p < .05. b: mean is significantly different from control D7 at p < .05. c: mean is significantly different from control D14 at
p < .05. d: mean is significantly different from control D21 at p < .05. e: mean is significantly different from osteo D14 p < .05. #: mean is
significantly different from osteo D3 p < .05. $: mean is significantly different from Osteo + Ex D3 p < .05. (B) Western blot of Control, Osteo
and Osteo+Ex cells in W1, W2, and W3 for GLP‐1R, RUNX2, RANK, and RANKL (from up to bottom) and β‐actin as ahousekeeping
control. Control: undifferentiated cells, Osteo: osteogenic differentiated cells, Osteo+Ex: osteogenic differentiated cells in presence of
exendin, W1: week‐1, W2: week‐2, W3: 3 weeks (C) Quantification of western blot using β‐actin as internal control for GLP‐1R, RUNX‐2,
RANK and RANKL. a: means are significantly different from control, p < .05. b: means are significantly different from osteo W1, p < .05. c:
means are significantly different from osteo W2, p < .05. d: means are significantly different from osteo W3, p < .05. Ad‐MSC, adipose
mesenchymal stem cell; RUNX‐2, runt‐related transcription factor‐2

decrease in its expression. Interestingly, osteogenic differentiation in the presence of exendin‐4 showed more decline in
its expression starting from W1 and continues towards the
third week of differentiation. These data showed that not
only does exendin‐4 improved expression of osteogenic
markers, but also had a profound effect on RANK/RANKL/
OPG axis. The quantification of the western blots for GLP1R,
RUNX‐2, RANK, and RANKL are displayed in Figure 4C.

4 | DISCUSSION
In this study, Ad‐MSCs were isolated, cultured and
characterized from rat epididymis. These cells fulfilled all
criteria of MSCs including plastic adherence, expression
of mesenchymal CD markers such as CD90, and lacking
hematopoietic CDs such as CD34 and have the
ability to differentiate down the osteogenic, adipogenic
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and chondrogenic lineages.5 These cells were able to
differentiate into osteocytes, and this was verified by
alizarin red staining and expression of bone markers,
such as RUNX‐2, OC, and Col‐1. Additionally, this
differentiation was associated with increased expression
of OPG, initial increase then a decrease in RANK and a
decreased expression of RANKL, favoring the balance
towards the osteoblastic activity rather than the osteoclastic activity.17 Interestingly, exendin‐4 could enhance
this osteogenic differentiation as verified by the increased
expression of OPG in D14 of differentiation, RUNX‐2, OC
and decreased expression of Col‐1. Importantly, exendin‐
4 also increased the expression of OPG and decreased
that of RANKL, shifting this balance more towards the
osteoblastic activity. These results indicate that Ad‐MSCs
are a good source for regenerative therapy of bones.
Besides, the RANK/RANKL/OPG is shifted towards the
osteoblastic activity upon osteogenic differentiation. In
addition, exendin‐4 enhances osteogenic differentiation
in part through this RANK/RANKL/OPG axis.
MSCs have long been used in regenerative medicine
with a special potential for bone repair, especially as they
have the ability to differentiate into osteoblasts as one of
their characterization criteria according to Dominici and
colleagues, 2006.5,31 MSCs isolated from adipose tissue
had gained more interest in the field of regenerative
medicine rather than other sources of MSCs, due to
various advantages. Ad‐MSCs can be easily isolated with
huge abundance and easier procedures than other MSCs
such as bone marrow and umbilical cord.32 It was shown
that Ad‐MSCs obtained from liposuction had almost 500
times more yield than cells isolated from bone marrow.1
This is very important as obtaining huge number of
MSCs of clinical grade is essential for future clinical
applications of MSCs in regenerative medicine. This was
experimentally very obvious, as the isolated cells started
to show the characteristic fibroblast‐like shape of MSCs,
just 1 week after isolation. These cells fulfilled all the
criteria of MSCs from P1, indicating that adipose tissue is
a real abundant source of MSCs, and can be used as a
model to study the MSCs differentiation into osteoblasts
or even other lineages.
Moreover, the role of MSCs in the treatment of bone
defects and bone repair has been elucidated long time
ago.33,34 MSCs from different sources have different
abilities towards the differentiation into osteocytes. One
study showed that either rat bone marrow (BM)‐MSCs or
periosteum MSCs are superior to Ad‐MSCs in osteogenic
differentiation. However, the same paper showed that as
for the colony forming assay, Ad‐MSCs was far more
superior to both types.35 This was confirmed with other
studies that showed human BM‐MSCs are superior to
Ad‐MSCs in osteogenic and cartilage differentiation.36,37
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However, these studies all agreed on the superior abilities
of Ad‐MSCs of proliferation and colony formation as
compared to BM‐MSCs. Actually, this criterion is
important for clinical applications of stem cells. In
addition, the abilities of these human cells may be
affected by the age of the donor. So, the balance between
the proliferation and differentiation abilities of the MSCs
from various sources should be taken in consideration in
the future clinical choice.
It is worth noting here that these Ad‐MSCs showed
increased expression of most of the osteogenic markers
till week 2 of differentiation, then no further increase was
observed in week 3 both at mRNA and protein levels.
This was obvious for RUNX‐2, OC and the decline of Col‐
1; the latter reached its peak even in week 1 of
differentiation. In addition, the western blot analysis
showed relative expression of osteogenic markers in the
control cells such as RUNX‐2, RANK and even RANKL.
This indicates that these rat Ad‐MSCs can reach
osteogenic maturation earlier than the usual 3‐week
differentiation period. Interestingly, in aprevious study,
Mohamed‐Ahmed and colleagues, 2018, used this early
osteogenic markers expression at week 2 as an evidence
of better osteogenic maturation of human BM‐MSCs than
Ad‐MSCs.37 Based on the results of early expression of
osteogenic markers in week 2 of differentiation, it can be
assumed that these rat Ad‐MSCs may have good
osteogenic differentiation and can be useful in studying
the mechanism of MSCs osteogenic differentiation, a
result that needs more confirmation and investigations.
Molecular inspection had led to an understanding of
the role of RANK/RANKL/OPG system in regulation of
bone resorption.17 RANKL signaling is vital for osteoclast
proliferation and differentiation.38,39 Its clinical inhibitor
denosumab is used clinically in the treatment of
osteoclasts‐related diseases such as osteoporosis.40,41 On
the other hand, another study showed that RANKL
reverse signaling promotes osteoblastic differentiation.42
Meanwhile, OPG is a soluble decoy receptor for RANKL,
which binds with it preventing its interaction with
RANK, and acts as an effective inhibitor of osteoclastogenesis.43 However, only few information is revealed
about this axis in osteogenic differentiation of MSCs.
As for RANK‐RANKL signaling in osteogenic differentiation of MSCs, Chen and his coworkers, 2018,
showed that RANK is expressed in BM‐MSCs, decreased
upon osteogenic differentiation and that RANK‐RANKL
signaling inhibits osteogenesis and bone formation.39
This came in accordance with this study's results where
this study showed that RANK is elevated at the
beginning of the osteogenic differentiation then
decreased towards the end of the differentiation.
Interestingly, RANKL was decreased from the beginning
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of the osteogenic differentiation. Meanwhile, soluble
OPG is elevated starting from first week of differentiation. These results indicate that upon differentiation of
Ad‐MSCs, these cells are activating the osteoblastic
proteins rather than the osteoclastic ones evidenced by
increased OPG/RANKL ratio. This study is almost the
only study that is mainly concerned with investigating
the whole axis of RANK/RANKL/OPG in the differentiation of MSCs; as these proteins are usually examined
separately as with Chen and his coworkers study, 2018 or
OPG is used as a mere osteogenic differentiation
marker26,39 especially that the secreted OPG was
examined in the media of osteogenic‐induced Ad‐MSCs.
Basically, the secretion of OPG by Ad‐MSCs may offer
several advantages for the use of Ad‐MSCs as a source of
cellular therapy for bone defects. First, as just shown, this
secreted OPG will direct the osteogenic differentiation of
Ad‐MSCs towards osteoblastogenesis rather than osteoclastogenesis with overall increased bone formation.
Secondly, an interesting study showed that BM‐MSCs
constitutively produce OPG and caused inhibition of
osteoclastogenesis, which was found beneficial for
inhibition of joint damage,44 a scenario which is likely
to be beneficial with Ad‐MSCs in the treatment of bone
defects, given that these cells showed considerable
secretion of OPG.
Finally, apart from the effect of OPG on the
osteoblast/osteoclast balance, it also affects the adipogenic/osteogenic differentiation balance of MSCs. It was
shown that OPG inhibits the adipogenic differentiation of
BM stromal cells and favors the osteogenic differentiation of these cells, preventing the formation of BM
adipocytes; which in a way supports the osteoblastic
activity.45 Actually, the current study results support this
OPG effect. Such benefits gained from the ability of Ad‐
MSCs to secrete OPG, qualify them to be the cells of
choice for the treatment of bone defects.
Furthermore, the effect of exendin‐4 was studied, as a
GLP‐1R agonist, on osteogenic differentiation and
RANK/RANKL/OPG axis. GLP‐1 has long been known
as a modulator of bone growth and remodeling.46 Also,
its agonist, exendin‐4, was known for its osteogenic effect
on BM‐MSCs.47 Similarly, exendin‐4 was shown to have a
prophylactic effect in osteopenia through enhancement
of bone formation.22
The results presented in the current study came in
accordance with exendin‐4 osteogenic potential, where
cells differentiated upon exendin‐4 addition showed
increased alizarin red staining, increased expression of
bone markers RUNX‐2 and OC, increase secretion of
OPG and even increased expression of GLP‐1R, a finding
shown previously.48 Ad‐MSCs upon osteogenic differentiation showed sustained expression of FOXO‐1 as an
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osteogenic player, with decreased expression of PPAR‐γ
as an adipogenic factor. In addition, exendin‐4 maintained expression of FOXO1 and decreased expression of
PPAR‐γ, indicating that exendin‐4 not only increased
osteogenic differentiation of Ad‐MSCs but also shifted
the adipogenic/osteogenic balance towards the osteogenic lineage.
Several studies showed that the potential of exendin‐4
to activate osteogenic differentiation of MSCs may be
accomplished through activation of various pathways,
including protein kinase A, β‐catenin, GSK‐β or MAP
kinase.12,47,49 However, the effect of exendin‐4 on the
RANK/RANKL/OPG axis was not tackled by these
studies. The results showed that exendin‐4 elevated
RANK expression initially, and then decreased its
expression similar to osteogenic differentiation without
exendin‐4. Importantly, exendin‐4 diminished expression
of RANKL and increased secretion of OPG. This clearly
indicates that exendin‐4 not only improved the osteogenic differentiation of Ad‐MSCs, but also increased
OPG/RANKL ratio with overall activation of osteoblastic
rather than osteoclastic activity. Accordingly, it can be
assumed that the exendin‐4 mediated improvement of
osteogenic differentiation can be attributed in part to the
effect of exendin‐4 on the RANK/RANKL/OPG axis, as a
potential new pathway accounting for exendin‐4 bone
effects, which requires further elucidation on both
normal bones and other stem cells biology.
Exendin‐4, as a GLP‐1R agonist, is a clinically
approved drug for type‐2 diabetes mellitus (DM). It is
well known that “weak bones” is a feature of types 1 and
2 DM with different mechanisms.50 This is very true to
the extent that “weak bones” can be considered as an
underestimated complication of DM.51 Since both
exendin‐4 and Ad‐MSCs have beneficial effects on
hyperglycemia and bone defects,52,53 therefore, coadministration of Ad‐MSCs and exendin‐4 can alleviate
hyperglycemia and improve bone formation simultaneously in diabetic patients. This notion requires further
preclinical and clinical investigation to confirm the
potential synergistic effect of these two therapeutic
modalities. In addition, another GLP‐1R agonist, namely
liraglutide, was found also to enhance the therapeutic
effects of BM‐MSCs in type 1 DM.54 Also, it was proved to
improve glucose metabolism and decrease β‐cell apoptosis when co‐injected with UC‐MSCs.55 Interestingly, it
was found to exert a bone protective effect in vivo
through increasing OPG/RANKL ratio.56 This data
indicates that further investigations on liraglutide effect
on osteogenic differentiation of MSCs and bone regeneration are warranted.
Unfortunately, there is a lack in the clinical studies
on the efficacy of GLP‐1R agonists in treatment of
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osteoporosis.57 Interestingly, exendin‐4 was tested for its
anti‐osteoporotic effect using a senescent osteoblast rat
mode and it was found to downregulate the expression of
senescence‐associated genes and upregulate the expression of bone‐related genes, indicating potential anti‐
osteoporotic effects of exendin‐4.58 In addition, several
studies showed that GLP‐1R agonists such as geniposide
and liraglutide can reverse the glucocorticoid‐induced
osteoporosis by slowing down bone resorption and
promoting osteogenic differentiation and bone formation.59,60 Moreover, GLP‐1 was found to be associated
with decreased osteoporotic risk in diabetic postmenopausal patients.61 However, it is still controversial
whether GLP‐1R agonists can prevent or treat diabetic
osteoporosis of fracture in clinical trials, a point warrants
more research and studies.62,63
As for the clinical applications of Ad‐MSCs, there is
growing number of researchers start to explore the
potential use of MSCs from various sources in the
treatment of osteoporosis clinically.64,65 Previous studies
showed that Ad‐MSCs can enhance bone regeneration in
ovariectomized mice,66 rabbits67 or through its capacity
to differentiate down the osteogenic lineage,68 similar to
this current study. Although the clinical studies of Ad‐
MSCs utility in treatment of osteoporosis is still scarce,
however, Ad‐MSCs showed some success in treatment of
microfractures,69 bone defects70 and osteoarthritis.71
These preclinical and clinical studies clearly demonstrated the safety and efficacy of Ad‐MSCs. Despite that
Ad‐MSCs can provide a novel therapeutic approach to
various orthopedic diseases and is one of the most
promising seed cells in bone tissue engineering,65,72 more
studies are still needed to explore the proper cell dosage,
mode of administration and adverse reactions associated
with the use of Ad‐MSCs in the clinical applications.
The limitations of this study were using the Ad‐MSCs
from rats that hinders the direct application of these cells
in clinical settings. Future assessment of RANK/RANKL/
OPG axis and the exendin‐4 effects is warranted in other
human MSCs, such as bone marrow and adipose MSCs
with recommended preclinical and clinical applications
of these cells, in combination with exendin‐4 as a new
model for the treatment of bone defects especially in
diabetic patients. On the other hand, the results of this
study can be expanded to other MSCs types and include
other GLP‐1R agonists such as liraglutide or even
dipeptidyl peptidase‐4 (DPP‐4) inhibitors, i.e., gliptins
to prove the beneficial osteogenic effects of these drugs
either alone or in combination with MSCs in regeneration of bones and/or treatment of bone diseases such as
fractures or osteoporosis.
In summary, this study proved that Ad‐MSCs could
be a good source of MSCs for future clinical applications
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in the treatment of bone defects, especially due to
possessing good culture properties and good osteogenic
abilities. In addition, osteogenic differentiation is associated with activation of the osteoblastic high OPG/
RANKL ratio rather than the osteoclastic RANKL/RANK
signaling. Exendin‐4 has a potential ability in osteogenic
differentiation enhancement of Ad‐MSCs partially by
modulation of RANK/RANKL/OPG axis. This is the first
report on the RANK/RANKL/OPG axis during osteogenic differentiation of Ad‐MSCs, and also the first time
to point out RANK/RANKL/OPG mediated exendin‐4
enhancement of osteogenic differentiation.

5 | CONCLUSION
The presented findings showed that Ad‐MSCs are a good
source for cell‐based therapy of bone defects. Osteogenic
differentiation is associated with increased osteoblastic
rather than osteoclastic activity, confirmed by the
increased osteogenic markers RUNX‐2, OC and FOXO‐
1, elevated OPG/RANKL ratio and reduced RANK
expression. Exendin‐4 can improve the osteogenic
outcome of Ad‐MSCs differentiation, partially, by modulation of RANK/RANKL/OPG axis through elevating
GLP‐1R expression. Both Ad‐MSCs and exendin‐4 in
combination are promising approaches for developing
cell‐based therapy for bone defects in diabetes and other
conditions.
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